# Wegovy HD is a once-weekly injection that contains 7.2 milligrams of active ingredient semaglutide.

*business · news · 2026-04-07 · MarketScreener*

## Key points

- Novo Nordisk launched Wegovy HD, a 7.2 mg semaglutide injection, in the U.S.
- Wegovy HD enables average weight loss of 21% over 18 months in non-diabetic obese adults.
- Previously, the highest Wegovy dose was 2.4 mg, yielding about 18% average weight loss.
- Novo Nordisk seeks EU and U.K. approval for a 7.2 mg single-dose pen, decision expected later this year.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** United States, Denmark, United Kingdom, European Union

[Read the full story on MarketScreener](https://www.marketscreener.com/news/novo-nordisk-launches-higher-dose-wegovy-weight-loss-shot-in-u-s-ce7e51d3df8cfe26)

---

Canonical: https://newsio.io/n/dda26f7b-4c3f-4b76-b859-683346e5cf08/wegovy-hd-is-a-once-weekly-injection-that-contains-7-2-milligrams-of-active-ingr
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works